Ionis Pharmaceuticals (IONS) Financial Analysis & Valuation | Quarter Chart

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis... more
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. T... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$7.46BExchangeNASDAQ
SectorHealthcareIndustryBiotechnology
CountryUSCEOBrett Monia
IPO Date1991-05-17CAGR19.23%
Employees1,480Websitewww.ionispharma.com
Div. YieldPayout Ratio
Buy Back YieldTotal Yield
IONS chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
EV$13.11BP/E-13.73Forward P/E-39.95PEG
P/S76.94P/B152.93P/CF-135.53P/FCF-120.42
Sales$873.76MSales 1Y-7.45%Sales 3Y38.56%Sales 5Y27.05%
EPS$-3.27EPS 1Y86.02%EPS 3Y60.19%EPS 5Y-10.36%
Sales QoQ8.88%EPS QoQ23.21%Sales QoQ Avg-1.42%EPS QoQ Avg-44.62%
Gross Margin98.16%Operating Margin-68.09%Profit Margin-64.64%ROCE-22.21%
ROA-19%ROE-111%Altman Z Score1.05Piotroski Score2
Current Ratio7.89Quick Ratio7.73Cash Ratio1.11Op. CF Ratio1.79
Debt/Equity3.67Debt/Assets0.54Lt Debt/Equity4.27Lt Debt/Cap.0.79
Intrst Cov.-9.48Inventory Turnover0.32Asset Turnover0.29Receivables Turnover14.85
Enterprise Value$13.11BP/E Ratio-13.73
Forward P/E-39.95PEG Ratio
P/S Ratio76.94P/B Ratio152.93
P/CF Ratio-135.53P/FCF Ratio-120.42
EPS$-3.27EPS Growth 1Y86.02%
EPS Growth 3Y60.19%EPS Growth 5Y-10.36%
Revenue Growth 1Y-7.45%Gross Margin98.16%
Operating Margin-68.09%Profit Margin-64.64%
ROE-111%ROA-19%
ROCE-22.21%Current Ratio7.89
Quick Ratio7.73Cash Ratio1.11
Debt/Equity3.67Interest Coverage-9.48
Altman Z Score1.05Piotroski Score2